Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4UOY5)

Drug Name
TEN010 Drug Info
Indication
Disease Entry ICD 11 Status REF
Advanced solid tumour 2A00-2F9Z Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
54670351
TTD Drug ID
DM4UOY5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Bromodomain-containing protein 4 (BRD4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CPI-0610 DMPXOYJ Myelofibrosis 2A20.2 Phase 3 [3]
OTX-015 DMI8RG1 Acute myeloid leukaemia 2A60 Phase 1/2 [3]
PLX2853 DMX168L Acute myeloid leukaemia 2A60 Phase 1/2 [4]
RVX-208 DM1LO8K Alzheimer disease 8A20 Phase 1/2 [3]
INCB57643 DMBGU7V Advanced malignancy 2A00-2F9Z Phase 1/2 [4]
ABBV-744 DMTEA9C Acute myeloid leukaemia 2A60 Phase 1 [4]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [5]
GSK525762 DMPAWBN Haematological malignancy 2B33.Y Phase 1 [3]
AZD5153 DMW4GM2 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PMID26924192-Compound-104 DM346EU N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bromodomain-containing protein 4 (BRD4) TTRA6BO BRD4_HUMAN Modulator [3]

References

1 ClinicalTrials.gov (NCT02308761) A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.
2 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
3 Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
6 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.